Pro Medicus Limited (PMDIY) Q4 2026 Earnings Call Transcript

SA Transcripts 161.89K Followers Follow Pro Medicus Limited ( PMDIY ) Q4 2026 Earnings Call August 17, 2026 9:00 PM EDT

Company Participants

Sam Hupert - Co-Founder, CEO, MD & Executive Director

Conference Call Participants

Josh Kannourakis - Barrenjoey Markets Pty Limited, Research Division

David Stanton - Jefferies LLC, Research Division

Paul Mason - E&P, Research Division

Chris Cooper - JPMorgan Chase & Co, Research Division

Sarah Mann - MA Moelis Australia Securities, Research Division

Peter Meichelboeck - Select Equities Pty Ltd., Research Division

Madeleine Williams - Canaccord Genuity Corp., Research Division

Presentation

Operator Thank you for standing by. Welcome to the Pro Medicus Limited full year results briefing. [Operator Instructions] I would now like to hand the conference over to Dr. Sam Hupert, CEO. Please go ahead.

Sam Hupert Co-Founder, CEO, MD & Executive Director Thank you. Thanks, everybody, for joining us this morning for the full year results presentation. As you know, we currently work in 3 jurisdictions: Melbourne, our corporate headquarters and where we do our RIS development; Germany, our R&D and support for the Visage product; and North America, which is over 90% of our revenues and our largest core of people. So it's the biggest implementation group of people we have now overtaking both Europe and the U.S. and Melbourne.

In terms of the highlights for the year, I think I won't go through all the financials. We have some other slides to deal with it. But we did win one contract in Europe and nine in the U.S. worth a total of $407 million at minimums. We completed 6 out of 6 renewals for a total of $407 million, keeping our 100% renewal run rate intact. We have all our implementations on or ahead of schedule. Our cardiology option is gaining traction with U Colorado, Vancouver Clinic and others. We did announce 2 new products